Welcome by Dr. Gilbert Glady, President of the European Association of BioImmuneGenetic Medicine BI(G)MED) and creator of the method.
The entire conference will be translated into all languages (French, German, Spanish) simultaneously.
The program below is subject to change.
During this conference, a summary of recent advances and translational implications of epigenetic molecular events will be offered to understand the fundamental principles of BI(G)MED.
Prof. DAN PEER, PhD Tel Aviv UniversityPrecision nanomedicine laboratory RNA-Lipid Nanoparticles 2.0: From gene silencing to genome editing A growing body of work is highlighting genes and signaling pathways that are impaired in human disorders and that may be potential candidates for treatment. The development of nucleic acid-based tools...
Prof. Andreas Weinhaeusel, PhD University of Natural Resources and Applied Life Sciences Vienna, Austria Epigenomics FOR improving minimal invasive cancer diagnostics Related keywords: minimal invasive cancer diagnostics, biomarker development, DNA methylation, liquid biopsy The minimal invasiveness of diagnostic procedures is a prerequisite to enable broad clinical application such as early...
Prof. Peré Gascón, MD PhD Institute of Science and Technology of Barcelona, SpainSpecialty: Oncology and Hematology INTEGRATIVE ONCOLOGY: AN ONCOLOGIST’S VISION
Dr. Gilbert Glady, MD European Association for Immuno(g)enetic Biomedicine, France Dr. Narges Bahi-Jaber, PhD European Association of Immuno(G)enetic Biomedicine, France. Chronic EBV and autoimmune diseases – Standardization of serology with BI(G)MED
Presentation by different partner laboratories (TELETEST laboratory, NUGENIS laboratory and others) of new biological analyses useful in the diagnostic approach of BI(G)MED
Presentation by different partner laboratories (BIOVIS laboratory, Pachmann laboratory and others) of new biological analyses useful in the diagnostic approach of BI(G)MED